Board change

Avacta

29/04/2025 07:00

RNS Number : 5158G

Avacta Group PLC

29 April 2025

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Board change

 

LONDON and PHILADELPHIA - April 29, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces that Dr. Trevor Nicholls, one of the Group's non-executive directors, is retiring from the Board with effect from April 30, 2025. 

 

Mark Goldberg will take over as the Board's Chair of the Remuneration Committee

 

Shaun Chilton, non-executive Chairman commented:

 

"On behalf of the Avacta Board, I would like to thank Trevor for his valued contribution and dedication to the Company since his appointment in 2013 and wish him all the best for the future.

 

"As Avacta transitions to a pure-play biotechnology company, we have initiated the process of appointing an independent non-executive director with relevant international commercial experience and expertise. A further announcement will be made in due course."

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc
Michael Vinegrad, Group Communications
Director
www.avacta.com
Peel Hunt (Nomad and Joint Broker)
James Steel / Chris Golden
www.peelhunt.com
Panmure Liberum (Joint Broker)
Emma Earl / Will Goode / Mark Rogers
ICR Healthcare
Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert
www.panmureliberum.com
avacta@icrhealthcare.com
Investor Contact
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
Media Contact
Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com

 

 About Avacta - www.avacta.com

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
BOAPPUACCUPAGBR